Molnupiravir is an emerging treatment for COVID 19. Its clinical efficacy and safety in COVID 19 patients have been backed by evidence from Phase 3 clinical trial data including data from the Indian subcontinent. In this webinar, we will talk bout molnupiravir, its mechanism of action, safety and efficacy data, and also talk about the commonly asked questions about the dosage and administration of molnupiravir.
Dr. Ketan K Mehta
MD (Med), FCPS, FICP, FISE, FGSI Consultant Physician, Cardiopulmonologist Diabetologist, Mumbai
Dr. Shashank Joshi
President IAD, Past President ESI and API, Member, COVID -19 Task Force, Maharashtra
